Styleikin®
INN: ustekinumab
Description
Indications for use
Instruction
Ustekinumab is a human immunoglobulin IgG1k, a monoclonal antibody targeting interleukins IL-12 and IL-23, produced using recombinant DNA technology.
Mechanism of Action:
Ustekinumab is a fully human monoclonal antibody IgG1k that specifically binds to the shared p40 protein subunit of human interleukins IL-12 and IL-23. It can influence the clinical course of psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis by interrupting the Th1 and Th17 cytokine pathways, which play a central role in the pathogenesis of these diseases.
Adults
- Moderate to severe plaque psoriasis in cases of inadequate response, contraindications, or intolerance to other systemic therapies, including cyclosporine, methotrexate, or psoralen plus ultraviolet A (PUVA) therapy.
- Psoriatic arthritis – as monotherapy or in combination with methotrexate in cases of inadequate response to previous standard therapy.
Children
- Moderate to severe plaque psoriasis in children and adolescents aged 6 years and older with inadequate response or intolerance to other systemic therapies or phototherapy.
- Active juvenile psoriatic arthritis in children aged 5 years and older – as monotherapy or in combination with methotrexate.